Daiichi Sankyo Korea
- Address: East 15F,26, Eulji-ro 5-gil, Jung-gu, Seoul, Republic of Korea
- Website: www.daiichisankyo.co.kr/
Daiichi Sankyo Korea is the Korean subsidiary of Daiichi Sankyo Group, a global pharmaceutical company committed to delivering innovative medicines. The company first entered Korea in 1990 as Korea Daiichi Pharmaceutical Co., Ltd., changed its name to Daiichi Pharmaceutical Korea Co., Ltd. in 2004, and was relaunched in 2007 as Daiichi Sankyo Korea Co., Ltd. following the management integration of Japans Daiichi and Sankyo.
Since obtaining approval for the antihypertensive Olmetec in 2004, Daiichi Sankyo Korea has expanded its cardiovascular portfolio with products such as Sevikar and Sevikar HCT, the lipid-lowering agent Mevalotin, the antiplatelet agent Efient. The portfolio was further strengthened with the launch of the anticoagulant Lixiana in 2016 enabling the company to provide a broader range of therapies for cardiovascular disease management.
Since obtaining approval for the antihypertensive Olmetec in 2004, Daiichi Sankyo Korea has expanded its cardiovascular portfolio with products such as Sevikar and Sevikar HCT, the lipid-lowering agent Mevalotin, the antiplatelet agent Efient. The portfolio was further strengthened with the launch of the anticoagulant Lixiana in 2016 enabling the company to provide a broader range of therapies for cardiovascular disease management.